Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use
Background: little is known about the incidence and characteristics of multisystem immune-related adverse events (irAEs) associated with dual-agent ipilimumab and nivolumab use. Methods: A retrospective cohort review was completed that included cancer patients seen at the Juravinski Cancer Centre wh...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/1/28 |